SALT LAKE CITY, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in
the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic
treatments, announces that Jay M. Moyes has been named to the company’s Board as an independent director, effective immediately.
Moyes brings more than 30 years of healthcare industry expertise in senior-level financial positions and has significant governance
experience from Board memberships at publicly traded healthcare companies. His appointment expands Predictive’s Board to
five.
“We are delighted to attract a professional of Jay’s caliber as we build out Predictive’s Board with proven leaders to support
our strategy of bringing proprietary genetic-based diagnostics and therapeutics to market,” said Bradley C. Robinson, CEO of
Predictive Technology Group. “Jay’s extensive financial background in companies spanning from development-stage to commercial
operations in diagnostics, genetics and therapeutics makes him ideally suited for this role. His wealth of governance experience
from many years on multiple healthcare Boards will be particularly valuable, and we are excited to welcome Jay to our Board.”
“I’m delighted to join this company on the cutting-edge of precision medicine,” said Moyes. “Predictive’s approach to
using proprietary, extensive genetic data analytics to bring novel diagnostics and therapeutics to underserved markets in women’s
health and spinal disease positions it to make important contributions to improving health care. I look forward to working toward
achieving the company’s goals.”
Moyes previously served as Chief Financial Officer and Director of the publicly traded biomaterials company Amedica Corporation,
now SINTX Technologies, where he managed the company’s IPO and listing on NASDAQ, and as Chief Financial Officer at publicly
traded CareDx, a molecular diagnostics company where he introduced a strategy to reach profitability. Prior to that he held senior
finance positions including Chief Financial Officer during his 14-year tenure at publicly traded Myriad Genetics. In
addition to overseeing all financial aspects at Myriad as the company transitioned from 10 to more than 900 employees, he was
instrumental in raising more than $500 million in public and private financings. He previously was Vice President of Finance and
Chief Financial Officer of Genmark, a private genetics company. Moyes began his career in public accounting at KPMG.
Moyes serves on the Boards of Directors of Achieve Life Sciences (NASDAQ: ACHV), BioCardia (OTC/QB: BCDA) and Puma Biotechnologies (NYSE: PBYI). In addition to Amedica, he previously was a
director and Chairman of the Audit Committee of both Osiris Therapeutics (NASDAQ: OSIR) and Integrated Diagnostics. He also served
as a member of the Board of Trustees of the Utah Life Science Association. Moyes holds a BA in economics from Weber State
University and an MBA from the University of Utah.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and
companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive
Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue
products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that
assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively.
Additional information is available at Predtechgroup.com; Predrx.com and Predictivebiotech.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially
forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and
demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new
product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional
intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may
identify from time to time in the future.
Contact:
Investors
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100